Pharma Major-Sanofi India Reports 8 Per Cent Growth in Q4 2024 Net Sales Amid Strategic Demerger
Total revenue from operations for the full year 2024 was Rs 2,013.2 crore, showing a slight increase from Rs 1,996.1 crore in 2023.
Sanofi India Limited (SIL) has reported an 8 per cent increase in net sales for the fourth quarter of 2024, following the strategic demerger of its consumer healthcare business, effective June 1, 2024. For the quarter ending December 31, 2024, the company’s standalone profit from operations stood at Rs 108 crores, marking a 21 per cent increase from Rs 90 crores in the same period of the previous year. Total revenue from operations for the full year 2024 was Rs 2,013.2 crore, showing a slight increase from Rs 1,996.1 crore in 2023.
The net profit from continuing operations for the year was Rs 313.7 crore, a decline from Rs 364.6 crore in 2023. Earnings per share (EPS) for continuing operations were Rs 136.21, down from Rs 158.31 in the previous year. The demerger led to the derecognition of assets and liabilities related to the consumer healthcare business, impacting overall financials. The company has recommed a final dividend of Rs 117 per equity share, subject to shareholder approval.
DSIJ's DSIJ's ‘Mid Bridge’ service recommends well researched Mid-Cap stocks for smart investing. If this interests you, do download the service details here.
Sanofi India’s diabetes portfolio showed strong performance with double-digit growth for Toujeo® and the successful launch of Soliqua®. The company also announced new partnerships in the Central Nervous System (CNS) and Cardiovascular (CV) sectors, aimed at expanding reach and operations. The focus remains on improving operational efficiency and expanding the availability of both established and innovative products in India.
Sanofi India Limited, a prominent player in the pharmaceutical industry, has a longstanding presence in India, spanning nearly seven decades. The company is dedicated to promoting health across the spectrum, from prevention to treatment. Sanofi India is involved in various initiatives, including the India Charitable Access Program (InCAP), which provides free treatment for Lysosomal Storage Disorders. The company operates a world-class manufacturing site in Goa, which serves both domestic and international markets. Additionally, Sanofi India has established a global talent hub in Hyderabad, providing a range of services worldwide. Recognized for its excellence in people practices, Sanofi India comprises local entities such as Sanofi India Limited, Sanofi Healthcare India Pvt. Ltd., and Sanofi Consumer Healthcare India Limited.
Disclaimer: The article is for informational purposes only and not investment advice.